2 clips
a16z Podcast · Vasant Narasimhan
Novartis CEO explains how running multiple business units with different economics forced strategic capital misallocation. He describes the tough trade-offs between optimizing their pharmaceutical business versus investing in generics and devices, ultimately leading to a major corporate restructuring.
Novartis CEO Vasant Narasimhan describes the strategic decision to transform the company into a pure-play biopharmaceuticals business. He explains how they exited the consumer health business through a GSK joint venture and focused on specific therapeutic areas they believed would have the greatest impact.
